Using TMS to Increase Executive Function in Older Adults

NCT ID: NCT02767323

Last Updated: 2021-04-05

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

184 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-15

Study Completion Date

2020-03-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cognitive decline and dementia have become important public health issues in our time as medical science has increased lifespan and our society becomes progressively older. A great deal of the cognitive decline due to aging can be explained by decline in working memory (WM), a mental function central to cognition in which aging deficits appear almost universally. Attempts to use WM training to increase WM ability in older adults has had some success, but the transfer of performance enhancements caused by this training to other cognitive skills is controversial. Another intervention that shows much promise is noninvasive stimulation of cerebral cortex using transcranial magnetic stimulation (TMS), which has been shown to increase performance in many cognitive tasks.

Here, the investigator proposes to use fMRI-guided rTMS to enhance working memory performance. This will be achieved through three Aims. In the first, registered on this record, the investigator will stimulate both old and young healthy adults while they perform the WM task that will engage the frontoparietal network. To define the optimal rTMS target, rTMS will be applied over the dorsolateral prefrontal cortex (DLPFC: Aim 1a); or over the parietal cortex (PC: Aim 1b). These regions are involved not only in the maintenance of items in WM, but also in their manipulation, therefore applying rTMS over these areas should create WM performance enhancements that will be long-lasting. In Aim 1c, a direct within-subject comparison of these 2 targeted sites is performed.

In the second and third Aims, older adults will receive active or sham rTMS over the optimal target (defined in Arm 1) during two weeks of daily sessions while they perform the WM tasks. In the second Aim, the investigator hopes to demonstrate that the cumulative effect of multiple TMS sessions, in tandem with the synergistic effects of simultaneous TMS + WM training, create WM performance enhancements greater than those found with WM training alone, whose effects are long-lasting, continuing a month following the course of TMS sessions. In the third, the investigator will investigate whether the WM enhancements generated by the two weeks of TMS sessions will generalize to other cognitive tasks. The success of these 3 Aims will provide proof in principle for long-lasting, transferable effects of TMS in remediating WM and more general cognitive deficits due to aging, and point to a possible non-invasive brain stimulation therapy for cognitive decline in healthy aging and in dementia. This record is a reflection of Aim1, Aim 2 and 3 will be registered separately.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active or Sham rTMS over the DLPFC (Aim1a)

excitatory rTMS applied over the DLPFC (fMRI-guided). Active and Sham rTMS will be tested in a within subject design

Group Type EXPERIMENTAL

rTMS

Intervention Type DEVICE

excitatory 5Hz rTMS will be used

Sham rTMS

Intervention Type DEVICE

an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used

Active or Sham rTMS over the Parietal cortex (Aim1b)

excitatory rTMS applied over the parietal cortex (fMRI-guided). Active and Sham rTMS will be tested in a within subject design

Group Type EXPERIMENTAL

rTMS

Intervention Type DEVICE

excitatory 5Hz rTMS will be used

Sham rTMS

Intervention Type DEVICE

an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used

Active or Sham rTMS over the DLPFC and the Parietal cortex (Aim1c)

excitatory rTMS applied over the DLPFC and the parietal cortex (fMRI-guided). Active and Sham rTMS will be tested in a within subject design

Group Type EXPERIMENTAL

rTMS

Intervention Type DEVICE

excitatory 5Hz rTMS will be used

Sham rTMS

Intervention Type DEVICE

an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rTMS

excitatory 5Hz rTMS will be used

Intervention Type DEVICE

Sham rTMS

an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age Restrictions: Young Group (from 18 to 35 years old), Elderly Group (from 60 to 80 years old).
* Use of effective method of birth control for women of childbearing capacity.
* Willing to provide informed consent.

Exclusion Criteria

* Current or recent (within the past 6 months) history of substance abuse or dependence.
* Current serious medical illness.
* History of seizure, epilepsy, stroke, brain surgery, head injury, cranial metal implants, known structural brain lesion, devices that may be affected by rTMS or MRI (pacemaker, medication pump, cochlear implant, implanted brain stimulator)
* Inability or unwilling to give informed consent.
* Diagnosed any Axis I DSM-IV disorder (MINI, DSM-IV).
* For subjects age \> 59 years, a total scaled score \< 8 on the Dementia Rating Scale-2.
* Clinically defined neurological disorder.
* Increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure, or currently taking medication that lowers the seizure threshold.
* Claustrophobia (MRI scanner).
* Pregnancy.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Aging (NIA)

NIH

Sponsor Role collaborator

Duke University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lawrence Appelbaum

Role: PRINCIPAL_INVESTIGATOR

Duke University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Duke University Medical Center

Durham, North Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Crowell CA, Davis SW, Beynel L, Deng L, Lakhlani D, Hilbig SA, Palmer H, Brito A, Peterchev AV, Luber B, Lisanby SH, Appelbaum LG, Cabeza R. Older adults benefit from more widespread brain network integration during working memory. Neuroimage. 2020 Sep;218:116959. doi: 10.1016/j.neuroimage.2020.116959. Epub 2020 May 20.

Reference Type DERIVED
PMID: 32442638 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R01AG050618-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

Pro00065334

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

dTMS for Subjective Cognitive Decline
NCT06095063 RECRUITING NA
Functional Connectivity as a Biomarker of rTMS
NCT03050801 COMPLETED PHASE1/PHASE2
rTMS in Older Adults With MCI and AUD
NCT05896332 ACTIVE_NOT_RECRUITING PHASE1